Santen Pharmaceutical Co., Ltd.

    Jurisdiction
    Japan
    LEI
    529900TPT3I7C17MIM03
    ISIN
    JP3336000009 (4536.T)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - General

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Read full profile

    Fundamentals

    Net revenue
    €1.73B
    Gross margin
    55.5%
    EBIT
    €289.67M
    EBIT margin
    16.7%
    Net income
    €209.39M
    Net margin
    12.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A N/A
    N/A N/A
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    ¥19.00
    Ex date
    Payment date
    Dividend payout ratio
    33.4%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: August 7, 2022 (Q1 2022)

    Add to watchlist

    Notifications